Latamoxef-induced coagulation disorders: Incidence and risk factors.

WHAT IS KNOWN AND

OBJECTIVE

To observe the effect of latamoxef on coagulation function and to analyse its risk factors.

METHODS

A retrospective cohort study was performed to compare patients receiving latamoxef versus those treated with ceftazidime. Baseline characteristics and coagulation parameters were recorded and analysed to explore whether treatment with latamoxef increased the risks of coagulation disorders and bleeding.

RESULTS AND DISCUSSION: A total number of 162 patients receiving latamoxef and 93 patients receiving ceftazidime were included. Haemorrhagic events were similar between groups, but patients receiving latamoxef had a higher risk of coagulation disorders compared to those receiving ceftazidime. Multivariate analysis revealed that the exposure of antibiotics, especially the cumulative defined daily doses (DDDs), and the nutrition risk may be the predictors of coagulation disorders.

WHAT IS NEW AND

CONCLUSION

Latamoxef might induce coagulation disorders. Cumulative DDDs and the nutrition risk were linked with coagulation disorders.